Abselion
Latest round
- Series A
Last raised
- Dec 2024
Total raised
- $11M
Investors
- 9
About Abselion
Established in 2018 by CEO Ruizhi Wang and based in Cambridge, UK, Abselion, formerly known as HexagonFab, provides automated advanced protein quantification technology, facilitating precise analysis of biologics for research and development in pharmaceuticals and biotechnology. Abselion's core product offering is the Amperia benchtop instrument, which simplifies the quantification of biologics, including antibodies, adeno-associated viruses (AAVs), and other proteins from crude samples. The device utilises redox electrochemical detection (RED), converting protein binding into an electrical signal, eliminating the need for optical components, and enabling a compact, low-maintenance design. The Amperia is engineered for sensitivity and specificity, allowing for effective quantification with minimal sample preparation required. Amperia enhances laboratory workflows and is compatible with standard 96-well plates to facilitate up to four parallel measurements during various stages of biologics research, including discovery and process development. The company targets a global client base that includes research institutions, biotechnology firms, and pharmaceutical companies, focusing on markets in North America, Europe, and Asia.
Who invested in Abselion
9 investors across 2 rounds
See all investors in Abselion
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abselion
Who invested in Abselion?
Abselion has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abselion raised?
Abselion has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Abselion last raise money?
Abselion's most recent round on record is a Series A, in Dec 2024.
What does Abselion do?
Established in 2018 by CEO Ruizhi Wang and based in Cambridge, UK, Abselion, formerly known as HexagonFab, provides automated advanced protein quantification technology, facilitating precise analysis of biologics for research and development in pharmaceuticals and biotechnology.
Where is Abselion headquartered?
Abselion is headquartered in Cambridge, UK.
Which VCs invest in companies like Abselion?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Abselion's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Abselion? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.